Adamis Pharmaceuticals Changes Name To DMK Pharmaceuticals To Reflect New Strategic Focus; Company's Common Stock Is Expected To Trade Under The New Nasdaq Ticker Symbol "DMK" On Or About September 8, 2023
Portfolio Pulse from Happy Mohamed
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has announced a name change to DMK Pharmaceuticals Corporation, reflecting a new strategic focus on advancing small molecules for the treatment of substance use disorders. The company's common stock is expected to trade under the new Nasdaq ticker symbol 'DMK' from September 8, 2023. The company is developing DPI-125, a novel molecule for the treatment of opioid use disorder and moderate to severe pain. DMK expects several potential significant milestones for DPI-125 by the end of 2024.
September 07, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Adamis Pharmaceuticals is changing its name to DMK Pharmaceuticals and will trade under the new ticker 'DMK' from September 8, 2023. The company is focusing on the development of DPI-125 for the treatment of opioid use disorder and moderate to severe pain.
The name change and new ticker symbol reflect a strategic shift in the company's focus. This could potentially attract new investors interested in the substance use disorder treatment market. However, the impact on the stock price in the short term is uncertain as it will depend on the market's perception of the company's new direction and the potential of its lead compound, DPI-125.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100